VOYA Investment Management
STML

VOYA Investment Management’s Stemline Therapeutics, Inc. STML Stock Holding History

VOYA Investment Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,713
Closed -$105K – 2713
2020
Q1 		$105K Hold
21,713
– – ﹤0.01% 2331
2019
Q4 		$231K Buy
21,713
+4,463
+26% +$44.3K ﹤0.01% 2311
2019
Q3 		$180K Buy
17,250
+1,313
+8% +$17.2K ﹤0.01% 2271
2019
Q2 		$244K Buy
15,937
+1,415
+10% +$20.5K ﹤0.01% 2193
2019
Q1 		$187K Buy
14,522
+3,453
+31% +$39K ﹤0.01% 2291
2018
Q4 		$105K Hold
11,069
– – ﹤0.01% 2393
2018
Q3 		$184K Hold
11,069
– – ﹤0.01% 2365
2018
Q2 		$178K Hold
11,069
– – ﹤0.01% 2398
2018
Q1 		$169K Hold
11,069
– – ﹤0.01% 2370
2017
Q4 		$173K Hold
11,069
– – ﹤0.01% 2392
2017
Q3 		$123K Hold
11,069
– – ﹤0.01% 2510
2017
Q2 		$102K Buy
+11,069
New +$92.3K ﹤0.01% 2569
2013
Q4 		– Sell
-7,815
Closed -$354K – 2543
2013
Q3 		$354K Buy
+7,815
New +$255K ﹤0.01% 2175

VOYA Investment Management's STML Position: Q2 2020 in Review

VOYA Investment Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 21,713 shares — an estimated $105K sold.

VOYA Investment Management first reported a position in STML in Q3 2013 and held it in 13 quarters. The position peaked at $354K in Q3 2013. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • VOYA Investment Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • VOYA Investment Management sold 21,713 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $105K.
  • VOYA Investment Management first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 13 quarters.
  • VOYA Investment Management's Stemline Therapeutics, Inc. position peaked at $354K in Q3 2013.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on VOYA Investment Management's 13F filing for Q2 2020, filed 14 Aug 2020.